PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC (CROSBI ID 683232)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Khanna, Dinesh ; Lin, Celia J. F. ; Goldin, Jonathan ; Kim, Grace ; Kuwana, Masataka ; Allanore, Yannick ; Batalov, Anastas ; Butrimiene, Irena ; Carreira, Patricia ; Matucci-Cerinic, Marco ; Distler, Oliver ; Martinović Kaliterna, Dušanka ; Mihai, Carina ; Mogensen, Mette ; Olesińska, Marzena ; Pope, Janet ; Riemekasten, Gabriela ; Rodriguez-Reyne, Tatiana Sofía ; Santos, Maria Jose ; van Laar, Jacob M. ; Spotswood, Helen ; Siege, Jeffrey ; Jahreis, Angelika ; Furst, Daniel ; Denton, Christopher
engleski
PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC
The primary mRSS endpoint was not met ; however, TCZ Tx resulted in clinically relevant differences in FVC with preservation of LFS and improvement in fibrosis, measured by HRCT, in SSc pts.
LUNG FUNCTION, TOCILIZUMAB, SSc
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
202-202.
2019.
objavljeno
Podaci o matičnoj publikaciji
Annals of the Rheumatic Diseases
Podaci o skupu
Annual European Congress of Rheumatology (EULAR 2019)
predavanje
12.06.2019-15.06.2019
Madrid, Španjolska
